US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
US5541308A
(en)
|
1986-11-24 |
1996-07-30 |
Gen-Probe Incorporated |
Nucleic acid probes for detection and/or quantitation of non-viral organisms
|
DE3834636A1
(de)
|
1988-10-11 |
1990-04-19 |
Max Planck Gesellschaft |
Verfahren zur analyse von laengenpolymorphismen in dna-bereichen
|
US5766847A
(en)
|
1988-10-11 |
1998-06-16 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Process for analyzing length polymorphisms in DNA regions
|
US6867195B1
(en)
|
1989-03-21 |
2005-03-15 |
Vical Incorporated |
Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
US5608046A
(en)
|
1990-07-27 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Conjugated 4'-desmethyl nucleoside analog compounds
|
FR2675803B1
(fr)
|
1991-04-25 |
1996-09-06 |
Genset Sa |
Oligonucleotides fermes, antisens et sens et leurs applications.
|
WO1993001286A2
(en)
|
1991-06-28 |
1993-01-21 |
Massachusetts Institute Of Technology |
Localized oligonucleotide therapy
|
CA2082411A1
(en)
|
1991-06-28 |
1992-12-29 |
Robert D. Rosenberg |
Localized oligonucleotide therapy
|
US6200747B1
(en)
|
1992-01-28 |
2001-03-13 |
North Shore University Hospital Research Corp. |
Method and kits for detection of fragile X specific, GC-rich DNA sequences
|
US5869252A
(en)
|
1992-03-31 |
1999-02-09 |
Abbott Laboratories |
Method of multiplex ligase chain reaction
|
US6172208B1
(en)
|
1992-07-06 |
2001-01-09 |
Genzyme Corporation |
Oligonucleotides modified with conjugate groups
|
US5418139A
(en)
|
1993-02-10 |
1995-05-23 |
University Of Iowa Research Foundation |
Method for screening for cardiomyopathy
|
CA2116280A1
(en)
|
1993-03-05 |
1994-09-06 |
Marcy E. Macdonald |
Huntingtin dna, protein and uses thereof
|
NZ266386A
(en)
|
1993-05-11 |
1997-11-24 |
Univ North Carolina |
Use of antisense rna oligonucleotides in regulating gene expression
|
US5695933A
(en)
|
1993-05-28 |
1997-12-09 |
Massachusetts Institute Of Technology |
Direct detection of expanded nucleotide repeats in the human genome
|
US5741645A
(en)
|
1993-06-29 |
1998-04-21 |
Regents Of The University Of Minnesota |
Gene sequence for spinocerebellar ataxia type 1 and method for diagnosis
|
US5624803A
(en)
|
1993-10-14 |
1997-04-29 |
The Regents Of The University Of California |
In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
|
US5627263A
(en)
|
1993-11-24 |
1997-05-06 |
La Jolla Cancer Research Foundation |
Integrin-binding peptides
|
DE4342605A1
(de)
|
1993-12-14 |
1995-06-22 |
Buna Gmbh |
Funktionalisierte Olefinhomo- und -copolymere
|
US5962332A
(en)
|
1994-03-17 |
1999-10-05 |
University Of Massachusetts |
Detection of trinucleotide repeats by in situ hybridization
|
WO1995030774A1
(en)
|
1994-05-05 |
1995-11-16 |
Beckman Instruments, Inc. |
Oligonucleotide repeat arrays
|
US5968909A
(en)
|
1995-08-04 |
1999-10-19 |
Hybridon, Inc. |
Method of modulating gene expression with reduced immunostimulatory response
|
US5854223A
(en)
|
1995-10-06 |
1998-12-29 |
The Trustees Of Columbia University In The City Of New York |
S-DC28 as an antirestenosis agent after balloon injury
|
US20070173465A9
(en)
|
1995-10-11 |
2007-07-26 |
Monahan Sean D |
Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene
|
US7034009B2
(en)
|
1995-10-26 |
2006-04-25 |
Sirna Therapeutics, Inc. |
Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
|
US6300060B1
(en)
|
1995-11-09 |
2001-10-09 |
Dana-Farber Cancer Institute, Inc. |
Method for predicting the risk of prostate cancer morbidity and mortality
|
EP0882061B1
(de)
|
1996-02-14 |
2004-05-19 |
Isis Pharmaceuticals, Inc. |
Kohlenhydratmodifizierte luckenhafte oligonukleotide
|
AU6469896A
(en)
|
1996-07-18 |
1998-02-10 |
Srl Inc. |
Method for the diagnosis of spinocerebellar ataxia type 2 and primers therefor
|
WO1998018920A1
(fr)
|
1996-10-30 |
1998-05-07 |
Srl, Inc. |
Fragments d'adnc du gene responsable de l'ataxie spino-cerebelleuse de type 2
|
US5853995A
(en)
|
1997-01-07 |
1998-12-29 |
Research Development Foundation |
Large scale genotyping of diseases and a diagnostic test for spinocerebellar ataxia type 6
|
US20020137890A1
(en)
|
1997-03-31 |
2002-09-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
WO1998043993A2
(en)
|
1997-03-31 |
1998-10-08 |
Yale University |
Nucleic acid catalysts
|
AU7265298A
(en)
|
1997-04-29 |
1998-11-24 |
Trustees Of Boston University |
Methods and compositions for targeted dna differential display
|
US6329501B1
(en)
|
1997-05-29 |
2001-12-11 |
Auburn University |
Methods and compositions for targeting compounds to muscle
|
US6514755B1
(en)
|
1998-08-18 |
2003-02-04 |
Regents Of The University Of Minnesota |
SCA7 gene and methods of use
|
US6280938B1
(en)
|
1997-08-19 |
2001-08-28 |
Regents Of The University Of Minnesota |
SCA7 gene and method of use
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
AU750947C
(en)
|
1997-09-22 |
2003-05-22 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Nucleic acid catalysts with endonuclease activity
|
US6130207A
(en)
|
1997-11-05 |
2000-10-10 |
South Alabama Medical Science Foundation |
Cell-specific molecule and method for importing DNA into a nucleus
|
JP3012923B2
(ja)
|
1998-01-26 |
2000-02-28 |
新潟大学長 |
Cagリピート病の治療薬
|
KR100280219B1
(ko)
|
1998-02-26 |
2001-04-02 |
이수빈 |
삼핵산 반복 서열을 이용한 신경정신 질환의 진단 방법 및 진단 시약
|
US6683173B2
(en)
|
1998-04-03 |
2004-01-27 |
Epoch Biosciences, Inc. |
Tm leveling methods
|
US6322978B1
(en)
|
1998-04-20 |
2001-11-27 |
Joslin Diabetes Center, Inc. |
Repeat polymorphism in the frataxin gene and uses therefore
|
WO1999055857A2
(en)
|
1998-04-29 |
1999-11-04 |
Ribozyme Pharmaceuticals, Inc. |
Nucleoside triphosphates and their incorporation into ribozymes
|
CA2334960C
(en)
|
1998-06-10 |
2012-01-03 |
Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh |
Combination of tgf-.beta. inhibition and immune stimulation to treat hyperproliferative diseases
|
US20030096955A1
(en)
|
1998-09-01 |
2003-05-22 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
JP2002525382A
(ja)
|
1998-09-25 |
2002-08-13 |
ザ チルドレンズ メディカル センター コーポレイション |
プロテインキナーゼの活性を選択的に調節するショートペプチド
|
US6172216B1
(en)
|
1998-10-07 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of BCL-X expression
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
DE69932346T2
(de)
|
1998-10-26 |
2007-07-05 |
Avi Biopharma, Inc., Portland |
Auf Morpholin basierendes p53-Antisense- Oligonucleotid und dessen Verwendungen
|
US6399575B1
(en)
|
1998-11-10 |
2002-06-04 |
Auburn University |
Methods and compositions for targeting compounds to the central nervous system
|
US6133031A
(en)
|
1999-08-19 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of focal adhesion kinase expression
|
US20040226056A1
(en)
|
1998-12-22 |
2004-11-11 |
Myriad Genetics, Incorporated |
Compositions and methods for treating neurological disorders and diseases
|
US20020049173A1
(en)
|
1999-03-26 |
2002-04-25 |
Bennett C. Frank |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
US6379698B1
(en)
|
1999-04-06 |
2002-04-30 |
Isis Pharmaceuticals, Inc. |
Fusogenic lipids and vesicles
|
IL145586A0
(en)
|
1999-04-08 |
2002-06-30 |
Oasis Biosciences Inc |
Antisense oligonucleotides comprising universal and/or degenerate bases
|
JP2000325085A
(ja)
|
1999-05-21 |
2000-11-28 |
Masafumi Matsuo |
デュシェンヌ型筋ジストロフィー治療剤
|
US20030236214A1
(en)
|
1999-06-09 |
2003-12-25 |
Wolff Jon A. |
Charge reversal of polyion complexes and treatment of peripheral occlusive disease
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US6355481B1
(en)
|
1999-06-18 |
2002-03-12 |
Emory University |
Hybridoma cell line and monoclonal antibody for huntingtin protein
|
WO2001016312A2
(en)
|
1999-08-31 |
2001-03-08 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid based modulators of gene expression
|
CA2386239A1
(en)
|
1999-10-04 |
2001-04-12 |
University Of Medicine And Dentistry Of New Jersey |
Methods for identifying rna binding compounds
|
US6165786A
(en)
|
1999-11-03 |
2000-12-26 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of nucleolin expression
|
EP1257639A2
(de)
|
2000-02-08 |
2002-11-20 |
Ribozyme Pharmaceuticals, Inc. |
Nukleozyme mit endonuklease aktivität
|
WO2005019453A2
(en)
|
2001-05-18 |
2005-03-03 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
|
CN1311202A
(zh)
*
|
2000-02-29 |
2001-09-05 |
复旦大学 |
一种新的多肽——人反转录相关因子22和编码这种多肽的多核苷酸
|
EP1133993A1
(de)
|
2000-03-10 |
2001-09-19 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Verbingungen zur Behandlung der spinalen Muskelatrophie
|
AU4819101A
(en)
|
2000-04-13 |
2001-10-30 |
University Of British Columbia, The |
Modulating cell survival by modulating huntingtin function
|
US6653467B1
(en)
|
2000-04-26 |
2003-11-25 |
Jcr Pharmaceutical Co., Ltd. |
Medicament for treatment of Duchenne muscular dystrophy
|
AU2001261063A1
(en)
|
2000-04-28 |
2001-11-12 |
Xiao Xiao |
Dna sequences encoding dystrophin minigenes and methods of use thereof
|
EP1278761B1
(de)
|
2000-05-01 |
2005-04-06 |
Hybridon, Inc. |
Modulation von oligonukleotid cpg-vermittelter immunstimulation durch modifikation der nucleoside
|
AU2001259706A1
(en)
|
2000-05-09 |
2001-11-20 |
Reliable Biopharmaceutical, Inc. |
Polymeric compounds useful as prodrugs
|
ATE464378T1
(de)
|
2000-05-31 |
2010-04-15 |
Serono Genetics Inst Sa |
Verwendung des globulären kopfes von acrp30 zur verstärkung der zunahme von muskelmasse und - differenzierung
|
CN1326990A
(zh)
|
2000-06-07 |
2001-12-19 |
上海博德基因开发有限公司 |
一种新的多肽——人类dna cgg重复结合蛋白16.17和编码这种多肽的多核苷酸
|
US20030124523A1
(en)
|
2000-06-22 |
2003-07-03 |
Asselbergs Fredericus Alphonsus Maria |
Organic compounds
|
US6794192B2
(en)
|
2000-06-29 |
2004-09-21 |
Pfizer Inc. |
Target
|
RU2165149C1
(ru)
|
2000-07-03 |
2001-04-20 |
Шапошников Валерий Геннадьевич |
Система формования и упаковки изделий из сахарной ваты
|
JP4836366B2
(ja)
*
|
2000-08-25 |
2011-12-14 |
雅文 松尾 |
デュシェンヌ型筋ジストロフィー治療剤
|
US6727355B2
(en)
|
2000-08-25 |
2004-04-27 |
Jcr Pharmaceuticals Co., Ltd. |
Pharmaceutical composition for treatment of Duchenne muscular dystrophy
|
EP1191097A1
(de)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induktion von "exon-skipping" in eukaryotischen Zellen
|
AU3922802A
(en)
|
2000-10-02 |
2002-05-27 |
Keck Graduate Inst |
Methods for identifying nucleotides at defined positions in target nucleic acidsusing fluorescence polarization
|
ATE400656T1
(de)
|
2000-10-06 |
2008-07-15 |
Univ Michigan |
Mini-dystrophin nukleinsäure- und peptidsequenzen
|
US6623927B1
(en)
|
2000-11-08 |
2003-09-23 |
Council Of Scientific And Industrial Research |
Method of detection of allelic variants of SCA2 gene
|
AU2002236499A1
(en)
|
2000-11-30 |
2002-06-11 |
Uab Research Foundation |
Receptor-mediated uptake of peptides that bind the human transferrin receptor
|
US7001994B2
(en)
|
2001-01-18 |
2006-02-21 |
Genzyme Corporation |
Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
|
TW200526779A
(en)
|
2001-02-08 |
2005-08-16 |
Wyeth Corp |
Modified and stabilized GDF propeptides and uses thereof
|
KR100408053B1
(ko)
|
2001-02-13 |
2003-12-01 |
엘지전자 주식회사 |
에스알엠의 토크리플 저감방법
|
AU2002256359A1
(en)
|
2001-04-24 |
2002-11-05 |
Epigenesis Pharmaceuticals, Inc. |
Antisense and anti-inflammatory based compositions to treat respiratory disorders
|
WO2002092763A2
(en)
|
2001-05-11 |
2002-11-21 |
Regents Of The University Of Minnesota |
Intron associated with myotonic dystrophy type 2 and methods of use
|
US20050277133A1
(en)
|
2001-05-18 |
2005-12-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US20050282188A1
(en)
|
2001-05-18 |
2005-12-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050014172A1
(en)
|
2002-02-20 |
2005-01-20 |
Ivan Richards |
RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
|
IL143379A
(en)
|
2001-05-24 |
2013-11-28 |
Yissum Res Dev Co |
Oligonucleotide against human ache isoform r and its uses
|
US20030139435A1
(en)
|
2001-06-26 |
2003-07-24 |
Gulzar Ahmed |
N-heterocyclic inhibitors of TNF-alpha expression
|
DK1406667T3
(da)
|
2001-07-06 |
2008-06-16 |
Topigen Pharmaceuticals Inc |
Fremgangsmåder til at öge oligonukleotiders in vivo-effektivitet og hæmme inflammation hos pattedyr
|
CA2455424A1
(en)
|
2001-08-07 |
2003-02-20 |
University Of Delaware |
Compositions and methods for the prevention and treatment of huntington's disease
|
EP1419173B1
(de)
|
2001-08-10 |
2008-11-26 |
Novartis AG |
Peptide, die atherosklerotische schädigungen binden
|
US20060074034A1
(en)
|
2001-09-17 |
2006-04-06 |
Collins Douglas A |
Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
KR20030035047A
(ko)
|
2001-10-29 |
2003-05-09 |
(주)바이오코돈 |
Bmp-4 유전자 발현을 이용한 편평태선 질환의 치료 및진단방법
|
US20030166004A1
(en)
|
2001-11-01 |
2003-09-04 |
Jeno Gyuris |
Endothelial-cell binding peptides for diagnosis and therapy
|
US20030134790A1
(en)
|
2002-01-11 |
2003-07-17 |
University Of Medicine And Dentistry Of New Jersey |
Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
|
WO2003062258A1
(en)
|
2002-01-22 |
2003-07-31 |
The Cleveland Clinic Foundation |
Rnase l activator-antisense complexes
|
WO2003069330A1
(en)
|
2002-02-11 |
2003-08-21 |
The Trustees Of Columbia University In The City Of New York |
System and method for identifying proteins involved in force-initiated signal transduction
|
US20050096284A1
(en)
|
2002-02-20 |
2005-05-05 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US7771727B2
(en)
|
2002-03-01 |
2010-08-10 |
The Administrators Of The Tulane Educational Fund |
Conjugates of therapeutic or cytotoxic agents and biologically active peptides
|
US20040101852A1
(en)
|
2002-11-21 |
2004-05-27 |
Isis Pharmaceuticals Inc. |
Modulation of CGG triplet repeat binding protein 1 expression
|
ITRM20020253A1
(it)
|
2002-05-08 |
2003-11-10 |
Univ Roma |
Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche.
|
US20040102395A1
(en)
|
2002-11-22 |
2004-05-27 |
Isis Pharmaceuticals Inc. |
Modulation of IAP-like expression
|
EP1380644A1
(de)
|
2002-07-08 |
2004-01-14 |
Kylix B.V. |
Verwendung spezifischer TCF Zielgene zur Identifizierung von Medikamenten zur Behandlung von Krebsarten, insbesondere Colorectalkrebs, bei denen TCF/beta-catenin/WNT Signaltransduktion eine zentrale Rolle spielt
|
US7589059B2
(en)
|
2002-07-26 |
2009-09-15 |
Roche Madison Inc. |
Delivery of molecules and complexes to mammalian cells in vivo
|
US20050255086A1
(en)
|
2002-08-05 |
2005-11-17 |
Davidson Beverly L |
Nucleic acid silencing of Huntington's Disease gene
|
JP2005535318A
(ja)
|
2002-08-12 |
2005-11-24 |
ユニヴェルシテ ドゥ シェルブルック |
プレメッセンジャーrnaのスプライス部位選択の再プログラミング方法
|
GB0219143D0
(en)
|
2002-08-16 |
2002-09-25 |
Univ Leicester |
Modified tailed oligonucleotides
|
US20040219565A1
(en)
*
|
2002-10-21 |
2004-11-04 |
Sakari Kauppinen |
Oligonucleotides useful for detecting and analyzing nucleic acids of interest
|
DK1554305T3
(da)
|
2002-10-23 |
2007-04-23 |
Ct For Res And Technology Hell |
Prionprotein-bindende peptidsekvenser
|
US7892793B2
(en)
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
US7655785B1
(en)
|
2002-11-14 |
2010-02-02 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
EP1560931B1
(de)
|
2002-11-14 |
2011-07-27 |
Dharmacon, Inc. |
Funktionelle und hyperfunktionelle sirna
|
EP2530156B1
(de)
|
2002-11-25 |
2015-11-18 |
Masafumi Matsuo |
ENA-Nukleinsäurearzneimittel, die das Splicing im mRNA-Vorläufer verändern
|
GB0228079D0
(en)
|
2002-12-02 |
2003-01-08 |
Laxdale Ltd |
Huntington's Disease
|
EP1605978B1
(de)
|
2003-03-07 |
2010-09-01 |
Alnylam Pharmaceuticals Inc. |
Therapeutische zusammensetzungen
|
WO2004083432A1
(en)
|
2003-03-21 |
2004-09-30 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
US7514551B2
(en)
|
2003-04-03 |
2009-04-07 |
Enzo Life Sciences, Inc. |
Multisignal labeling reagents, and processes and uses therefor
|
CA2526893C
(en)
|
2003-05-14 |
2010-10-26 |
Japan Science And Technology Agency |
Inhibition of the expression of huntingtin gene
|
CN1829532A
(zh)
|
2003-06-02 |
2006-09-06 |
惠氏公司 |
肌肉抑制素(gdf8)抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途
|
DE60319354T2
(de)
|
2003-07-11 |
2009-03-26 |
Lbr Medbiotech B.V. |
Mannose-6-Phosphat Rezeptor vermittelter Gentransfer zu Muskelzellen
|
US20050048495A1
(en)
|
2003-08-29 |
2005-03-03 |
Baker Brenda F. |
Isoform-specific targeting of splice variants
|
US20050054752A1
(en)
|
2003-09-08 |
2005-03-10 |
O'brien John P. |
Peptide-based diblock and triblock dispersants and diblock polymers
|
US7355018B2
(en)
|
2003-09-30 |
2008-04-08 |
Regeneron Pharmaceuticals, Inc. |
Modified IGF1 polypeptides with increased stability and potency
|
US20050222009A1
(en)
|
2003-10-14 |
2005-10-06 |
Itschak Lamensdorf |
Dual phase - PNA conjugates for the delivery of PNA through the blood brain barrier
|
US20050191636A1
(en)
|
2004-03-01 |
2005-09-01 |
Biocept, Inc. |
Detection of STRP, such as fragile X syndrome
|
US20080207538A1
(en)
|
2004-03-11 |
2008-08-28 |
Lawrence David S |
Enhanced Production of Functional Proteins From Defective Genes
|
EP1735443A2
(de)
|
2004-04-14 |
2006-12-27 |
Sirna Therapeutics, Inc. |
Rna-interferenz-vermittelte behandlung von polyglutamin (polyq)-repeat-expansionskrankheiten unter verwendung von sina (short intefering nucleic acid)
|
AU2005248147A1
(en)
|
2004-05-11 |
2005-12-08 |
Alphagen Co., Ltd. |
Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
|
US20050288246A1
(en)
|
2004-05-24 |
2005-12-29 |
Iversen Patrick L |
Peptide conjugated, inosine-substituted antisense oligomer compound and method
|
KR20070026650A
(ko)
|
2004-05-27 |
2007-03-08 |
악셀레론 파마 인코포레이티드 |
케르베루스/코코 유도체 및 그의 용도
|
DK1766010T3
(da)
|
2004-06-28 |
2011-06-06 |
Univ Western Australia |
Antisense-oligonukleotider til induktion af exon-skipping og fremgangsmåder til anvendelse deraf
|
US7361468B2
(en)
|
2004-07-02 |
2008-04-22 |
Affymetrix, Inc. |
Methods for genotyping polymorphisms in humans
|
EP1618881A1
(de)
|
2004-07-20 |
2006-01-25 |
Santhera Pharmaceuticals (Schweiz) GmbH |
Verwendung von steroiden ohne glucocorticoid aktivität zur behandlung von muskulärer dystrophie
|
WO2006017522A2
(en)
|
2004-08-03 |
2006-02-16 |
University Of Utah Research Foundation |
Use of antisense oligonucleotides to effect translation modulation
|
US20060099612A1
(en)
|
2004-09-02 |
2006-05-11 |
Suntory Limited |
Method for analyzing genes of industrial yeasts
|
CA2582137A1
(en)
|
2004-10-05 |
2007-02-15 |
Wyeth |
Probe arrays for detecting multiple strains of different species
|
ITRM20040568A1
(it)
|
2004-11-18 |
2005-02-18 |
Uni Degli Studi Di Roma Tor Vergata |
Uso della tecnica "phage display" per l'identificazione di peptidi con capacita' di legame a cellule staminali/progenitore, peptidi cosi' ottenuti e loro usi.
|
US7838657B2
(en)
|
2004-12-03 |
2010-11-23 |
University Of Massachusetts |
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
|
KR100663277B1
(ko)
|
2004-12-20 |
2007-01-02 |
삼성전자주식회사 |
휴대단말기의 시스템 관련 이벤트 처리 장치 및 방법
|
US20060148740A1
(en)
|
2005-01-05 |
2006-07-06 |
Prosensa B.V. |
Mannose-6-phosphate receptor mediated gene transfer into muscle cells
|
US20120122801A1
(en)
|
2005-01-05 |
2012-05-17 |
Prosensa B.V. |
Mannose-6-phosphate receptor mediated gene transfer into muscle cells
|
AU2006210973A1
(en)
|
2005-01-31 |
2006-08-10 |
University Of Iowa Research Foundation |
Nucleic acid silencing of Huntington's Disease gene
|
WO2006108052A2
(en)
|
2005-04-06 |
2006-10-12 |
Genzyme Corporation |
Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
|
JP2008538500A
(ja)
|
2005-04-22 |
2008-10-30 |
アカデミス ツィーケンホイス ライデン |
SRタンパク質の結合に対する干渉とRNA二次構造に対する干渉による、mRNA前駆体におけるエクソン認識の調節
|
US7902352B2
(en)
|
2005-05-06 |
2011-03-08 |
Medtronic, Inc. |
Isolated nucleic acid duplex for reducing huntington gene expression
|
EP1885854B1
(de)
|
2005-05-06 |
2012-10-17 |
Medtronic, Inc. |
Verfahren und sequenzen zur unterdrückung der expression des huntington-gens in primaten
|
KR100764559B1
(ko)
|
2005-05-09 |
2007-10-08 |
한국표준과학연구원 |
Epsps 유전자 검색에 활용할 수 있는 fret형광검출용 프로브
|
EP3470072A1
(de)
|
2005-06-23 |
2019-04-17 |
Biogen MA Inc. |
Zusammensetzungen und verfahren zur modulation der smn2-spleissung
|
US20070161590A1
(en)
|
2005-06-28 |
2007-07-12 |
Medtronic, Inc. |
Methods and sequences to preferentially suppress expression of mutated huntingtin
|
DE102005030704A1
(de)
|
2005-06-29 |
2007-01-04 |
Autoliv Development Ab |
Sicherheitsgurt
|
EP2179737B1
(de)
|
2005-07-01 |
2013-08-14 |
Index Pharmaceuticals AB |
Modulierung der Reaktion auf Steroide
|
WO2007051045A2
(en)
|
2005-10-28 |
2007-05-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of huntingtin gene
|
US7906617B2
(en)
|
2005-12-15 |
2011-03-15 |
E. I. Du Pont De Nemours And Company |
Polyethylene binding peptides and methods of use
|
WO2007089584A2
(en)
|
2006-01-26 |
2007-08-09 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to huntingtin
|
EP2007365A2
(de)
|
2006-03-30 |
2008-12-31 |
PTC Therapeutics, Inc. |
Verfahren zur produktion von funktionellem protein aus dna mit nonsense-mutation und behandlung von damit assoziierten erkrankungen
|
WO2007123391A1
(en)
|
2006-04-20 |
2007-11-01 |
Academisch Ziekenhuis Leiden |
Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
|
EP1857548A1
(de)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Mittel und Verfahren zur Induktion von Exon-skipping
|
US7855053B2
(en)
|
2006-07-19 |
2010-12-21 |
The Regents Of The University Of California |
Methods for detecting the presence of expanded CGG repeats in the FMR1 gene 5′ untranslated region
|
CA2660523C
(en)
|
2006-08-11 |
2019-03-19 |
Prosensa Technologies B.V. |
Methods and means for treating dna repeat instability associated genetic disorders
|
US20090253744A1
(en)
|
2006-09-27 |
2009-10-08 |
Bakshi Raman K |
Acylated piperidine derivatives as melanocortin-4 receptor modulators
|
EP2087110A2
(de)
|
2006-10-11 |
2009-08-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Influenza-ziele
|
WO2008049078A1
(en)
*
|
2006-10-18 |
2008-04-24 |
Nastech Pharmaceutical Company Inc. |
Nicked or gapped nucleic acid molecules and uses thereof
|
WO2008103755A1
(en)
|
2007-02-20 |
2008-08-28 |
Mayo Foundation For Medical Education And Research |
Treating cancer with viral nucleic acid
|
PL381824A1
(pl)
|
2007-02-22 |
2008-09-01 |
Instytut Chemii Bioorganicznej Pan W Poznaniu |
Sekwencja siRNA, wektor, cel molekularny dla reagentów siRNA i wektorów wprowadzanych do komórek i tkanek, sposób oceny specyficzności wyciszania zmutowanego transkryptu, sposób badania oddziaływań enzymów szlaku interferencji RNA z transkryptami oraz zastosowanie sekwencji siRNA i wektora
|
AU2008271050B2
(en)
*
|
2007-06-29 |
2014-11-06 |
Sarepta Therapeutics, Inc. |
Tissue specific peptide conjugates and methods
|
EP2167135A2
(de)
|
2007-07-12 |
2010-03-31 |
Prosensa Technologies B.V. |
Moleküle für targeting von verbindungen auf verschiedene ausgewählte organe, gewebe oder tumorzellen
|
CA2693048C
(en)
|
2007-07-12 |
2016-10-18 |
Prosensa Technologies B.V. |
Molecules for targeting compounds to various selected organs or tissues
|
US9212205B2
(en)
|
2007-07-26 |
2015-12-15 |
University Of Rochester |
Nucleic acid binding compounds and methods of use
|
WO2009023855A2
(en)
|
2007-08-15 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
HUE028662T2
(en)
|
2007-10-26 |
2016-12-28 |
Academisch Ziekenhuis Leiden |
Preparations and methods for controlling muscle disorders
|
WO2009099326A1
(en)
|
2008-02-08 |
2009-08-13 |
Prosensa Holding Bv |
Methods and means for treating dna repeat instability associated genetic disorders
|
WO2009101399A1
(en)
|
2008-02-12 |
2009-08-20 |
Isis Innovation Limited |
Treatment of muscular dystrophy using peptide nucleic acid ( pna)
|
EP2105145A1
(de)
|
2008-03-27 |
2009-09-30 |
ETH Zürich |
Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
US8679750B2
(en)
|
2008-05-09 |
2014-03-25 |
The University Of British Columbia |
Methods and compositions for the treatment of Huntington'S disease
|
EP2119783A1
(de)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
|
WO2009144481A2
(en)
|
2008-05-30 |
2009-12-03 |
Isis Innovation Limited |
Conjugates for delivery of biologically active compounds
|
US20110152352A1
(en)
|
2008-06-10 |
2011-06-23 |
Tufts University |
Smad proteins control drosha-mediated mirna maturation
|
GB2457965B8
(en)
|
2008-07-01 |
2011-02-16 |
Renovo Ltd |
Methods and systems for determining efficacy of medicaments.
|
US20110218334A1
(en)
|
2008-07-11 |
2011-09-08 |
Alnylam Pharmaceuticals, Inc. |
PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS
|
JP2011529686A
(ja)
|
2008-07-29 |
2011-12-15 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
ポリグルタミンタンパク質発現の選択的阻害
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
CA2777486A1
(en)
|
2008-10-15 |
2010-04-22 |
4S3 Bioscience Inc. |
Methods and compositions for treatment of myotonic dystrophy
|
TR201902952T4
(tr)
*
|
2008-10-24 |
2019-03-21 |
Sarepta Therapeutics Inc |
Dmd için ekson atlama bileşimleri.
|
ES2532634T5
(es)
|
2008-10-27 |
2018-04-30 |
Biomarin Technologies B.V. |
Procedimientos y medios para el salto eficiente del exón 45 en el pre-ARNm de la distrofia muscular de Duchenne
|
US20100248239A1
(en)
|
2009-03-24 |
2010-09-30 |
Mayo Foundation For Medical Education And Research |
Methods and materials for detecting fragile x mutations
|
CN102625840A
(zh)
|
2009-04-10 |
2012-08-01 |
肌肉学研究协会 |
用于治疗疾病的三环dna反义寡核苷酸、组合物和方法
|
WO2010123369A1
(en)
|
2009-04-24 |
2010-10-28 |
Prosensa Technologies B.V. |
Oligonucleotide comprising an inosine for treating dmd
|
CN102803284B
(zh)
|
2009-06-08 |
2015-11-25 |
米拉根医疗公司 |
用于miRNA抑制剂和模拟物的化学修饰基序
|
CN102625809B
(zh)
|
2009-09-11 |
2015-06-24 |
Isis制药公司 |
亨廷顿表达的调节
|
KR102366851B1
(ko)
*
|
2009-11-12 |
2022-02-23 |
더 유니버시티 오브 웨스턴 오스트레일리아 |
안티센스 분자 및 이를 이용한 질환 치료방법
|
US20110166081A1
(en)
|
2009-12-03 |
2011-07-07 |
University Of Iowa Research Foundation |
Alpha-dystroglycan as a Protein Therapeutic
|
WO2011078797A2
(en)
|
2009-12-22 |
2011-06-30 |
Singapore Health Services Pte. Ltd |
Antisense oligonucleotides and uses threreof
|
WO2011078672A1
(en)
|
2009-12-24 |
2011-06-30 |
Prosensa Technologies B.V. |
Molecule for treating an inflammatory disorder
|
WO2011097614A1
(en)
|
2010-02-08 |
2011-08-11 |
Isis Pharmaceuticals, Inc. |
Mehods and compositions useful in diseases or conditions related to repeat expansion
|
WO2011097641A1
(en)
|
2010-02-08 |
2011-08-11 |
Isis Pharmaceuticals, Inc. |
Methods and compositions useful in treatment of diseases or conditions related to repeat expansion
|
NZ603606A
(en)
|
2010-05-28 |
2015-06-26 |
Sarepta Therapeutics Inc |
Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
|
JP5981428B2
(ja)
|
2010-07-19 |
2016-08-31 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
筋緊張性ジストロフィー・プロテインキナーゼ(dmpk)発現の調整
|
JP5775581B2
(ja)
|
2010-08-20 |
2015-09-09 |
レプリコール インコーポレーティッド |
オリゴヌクレオチドキレート錯体
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
WO2012109296A1
(en)
|
2011-02-08 |
2012-08-16 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center |
Antisense oligonucleotides
|
EP2699269A1
(de)
|
2011-04-22 |
2014-02-26 |
Prosensa Technologies B.V. |
Neue verbindungen zur behandlung, verzögerung und/oder prävention einer menschlichen genetischen erkrankung wie myotoner dystrophie typ 1 (dm1)
|
CN103619356B
(zh)
|
2011-05-05 |
2017-09-12 |
萨勒普塔医疗公司 |
肽寡核苷酸缀合物
|
EP2723864A2
(de)
*
|
2011-06-23 |
2014-04-30 |
Cold Spring Harbor Laboratory |
Phänokopisches krankheitsmodell
|
IN2014DN06220A
(de)
|
2011-12-28 |
2015-10-23 |
Nippon Shinyaku Co Ltd |
|
CA2862628C
(en)
|
2012-01-27 |
2021-08-24 |
Prosensa Technologies B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
SI2841578T1
(sl)
|
2012-04-23 |
2017-12-29 |
Biomarin Technologies B.V. |
Rna modulirajoči oligonukleotidi z izboljšanimi karakteristikami za zdravljenje nevromuskularnih motenj
|
AR091065A1
(es)
|
2012-05-18 |
2014-12-30 |
Replicor Inc |
Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
|
RU2674600C2
(ru)
|
2012-07-03 |
2018-12-11 |
Просенса Текнолоджиз Б.В. |
Олигонуклеотид для лечения пациентов с мышечной дистрофией
|